EQS-Adhoc: Appointment of new Chief Executive Officer of Carl Zeiss Meditec AG
|
EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Personnel decisions / Executive Board
Jena, 22 May 2026 Following the interim appointment of Mr. Andreas Pecher as CEO, the selection process initiated by Carl Zeiss Meditec AG (ISIN: DE0005313704) for the long-term succession of Chief Executive Officer has been successfully completed. At its meeting on 19 May 2026, the Supervisory Board of Carl Zeiss Meditec AG resolved to appoint Ms. Bronwyn Brophy O’Connor, currently CEO of the Vitrolife Group based in Sweden, as a member of the Management Board and to name her Chief Executive Officer. Before her current position, she had been working in leading roles in international companies like Thermo Fisher Scientific, Medtronic and Johnson & Johnson. The exact start date of her employment depends on ongoing negotiations with her current employer and will be announced as soon as possible. Until Ms. Brophy O’Connor takes office, Mr. Pecher will continue to serve as (interim) CEO of Carl Zeiss Meditec AG. Ms. Bronwyn Brophy O’Connor brings 25 years of professional experience in the fields of medical technology and Life Sciences. The appointment of Ms. Bronwyn Brophy O’Connor is intended to ensure the consistent continuation of Carl Zeiss Meditec AG's successfully initiated strategic realignment. In addition to her role as Chief Executive Officer of Carl Zeiss Meditec AG, Ms. Bronwyn Brophy O’Connor was also appointed Member of the Executive Board of Carl Zeiss AG. Mr. Andreas Pecher remains President and CEO of Carl Zeiss AG. This new appointment marks the successful conclusion of Carl Zeiss Meditec AG's process to resolve the long-term succession of the Chief Executive Officer.
Contact for investors and press Sebastian Frericks
End of Inside Information
22-May-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Carl Zeiss Meditec AG |
| Göschwitzer Str. 51-52 | |
| 07745 Jena, Germany | |
| Germany | |
| Phone: | +49 (0)3641 220-0 |
| Fax: | +49 (0)3641 220-112 |
| E-mail: | investors.med@zeiss.com |
| Internet: | www.zeiss.de/meditec-ag/ir |
| ISIN: | DE0005313704 |
| WKN: | 531370 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2332226 |
| End of Announcement | EQS News Service |
|
|
2332226 22-May-2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 1.335,45 | 1.646,79 | 1.902,84 | 2.089,30 | 2.066,13 | 2.227,65 | 2.100,00 | |
| EBITDA1,2 | 237,98 | 435,20 | 466,65 | 422,19 | 327,22 | 349,70 | 252,00 | |
| EBITDA-Margin3 | 17,82 | 26,43 | 24,52 | 20,21 | 15,84 | 15,70 | 12,00 | |
| EBIT1,4 | 177,55 | 373,61 | 396,88 | 348,12 | 194,45 | 223,32 | 160,00 | |
| EBIT-Margin5 | 13,30 | 22,69 | 20,86 | 16,66 | 9,41 | 10,03 | 7,62 | |
| Net Profit (Loss)1 | 123,42 | 237,52 | 295,91 | 292,01 | 180,15 | 142,35 | 70,00 | |
| Net-Margin6 | 9,24 | 14,42 | 15,55 | 13,98 | 8,72 | 6,39 | 3,33 | |
| Cashflow1,7 | 178,53 | 362,66 | 188,20 | 250,86 | 247,32 | 209,86 | 245,00 | |
| Earnings per share8 | 1,37 | 2,64 | 3,29 | 3,25 | 2,01 | 1,61 | 0,78 | |
| Dividend per share8 | 0,50 | 0,90 | 1,10 | 1,10 | 0,60 | 0,55 | 0,45 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PricewaterhouseCoopers
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Carl Zeiss Meditec | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 531370 | DE0005313704 | AG | 2.370,18 Mio € | 22.03.2000 | Halten | 9F2HVHPW+8C |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 17,67 | 32,73 | 0,54 | 12,06 | 1,15 | 11,29 | 1,06 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,10 | 0,60 | 0,55 | 2,08% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.03.2026 | 12.02.2026 | 12.05.2026 | 06.08.2026 | 11.12.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +3,60% | -26,15% | -33,75% | -53,79% | -8,62% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
